

Options

Use the drop-down menus to search the database:

Guideline:

Disease:

Agent:

Brand:

Route:

NCCN Category of Evidence:

Histology:

ICD-10:

[Reset Filters](#) [Print](#) 0 Ready to Print

No Longer Recommended Uses

Transparency: Process and Recommendations

Filters: Multiple Myeloma v.2.2018

Default Sort Showing 1 to 31 of 31 entries

Search:

Guideline - Disease	Agent	Brand	Pharmacologic Class	Histology	Route(s)	ICD-10 Codes	NCCN Recommended Use	NCCN Category	Order Template	FDA Indication
Multiple Myeloma - Multiple Myeloma Guideline Panel Disclosure	Bendamustine hydrochloride	Treanda®, Bendeka™	Alkylating agent	None	IV	C90.00, C90.02, C90.10, C90.12, C90.20, C90.22, C90.30, C90.32, C90.39, Z85.79	Therapy for previously treated myeloma for relapse or progressive disease <ul style="list-style-type: none"> in combination with lenalidomide and dexamethasone in combination with bortezomib and dexamethasone as a single agent (useful under some circumstances) 	2A	MUM35 MUM51 MUM73	Chronic Lymphocytic Leukemia: Bendamustine hydrochloride for injection is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first-line therapies other than chlorambucil has not been established. Non-Hodgkin's Lymphoma: Bendamustine hydrochloride for injection is indicated for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Multiple Myeloma - Multiple Myeloma	Bortezomib	Velcade®	Proteasome inhibitor	None	SC, IV	C90.00, C90.02, C90.10, C90.12, C90.20, C90.22, C90.30, C90.32, C90.39, Z85.79	Primary therapy for active (symptomatic) myeloma or for disease relapse after 6 months following primary induction therapy with the same regimen <ul style="list-style-type: none"> in combination with dexamethasone and lenalidomide (preferred regimen) in combination with dexamethasone and cyclophosphamide (preferred initial treatment in patients with acute renal insufficiency) 	1 for all others 2A for combination with dexamethasone in non-transplant	MUM13 MUM15 MUM16 MUM19 MUM40	Bortezomib for injection is indicated for the treatment of patients with multiple myeloma. Bortezomib for injection is indicated for the treatment of patients with mantle cell lymphoma.